- Home
- BDTX vs CBIO Comparison
BDTX vs CBIO Comparison
Compare BDTX & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BDTX
- CBIO
- Stock Information
- Founded
- BDTX 2014
- CBIO 2003
- Country
- BDTX United States
- CBIO United States
- Employees
- BDTX N/A
- CBIO N/A
- Industry
- BDTX Biotechnology: Biological Products (No Diagnostic Substances)
- CBIO
- Sector
- BDTX Health Care
- CBIO
- Exchange
- BDTX Nasdaq
- CBIO Nasdaq
- Market Cap
- BDTX 220.3M
- CBIO 209.8M
- IPO Year
- BDTX 2020
- CBIO N/A
- Fundamental
- Price
- BDTX $3.95
- CBIO $12.35
- Analyst Decision
- BDTX Strong Buy
- CBIO Strong Buy
- Analyst Count
- BDTX 5
- CBIO 5
- Target Price
- BDTX $10.40
- CBIO $25.60
- AVG Volume (30 Days)
- BDTX 812.4K
- CBIO 111.3K
- Earning Date
- BDTX 11-05-2025
- CBIO 11-23-2025
- Dividend Yield
- BDTX N/A
- CBIO N/A
- EPS Growth
- BDTX N/A
- CBIO N/A
- EPS
- BDTX 0.25
- CBIO N/A
- Revenue
- BDTX $70,000,000.00
- CBIO N/A
- Revenue This Year
- BDTX N/A
- CBIO N/A
- Revenue Next Year
- BDTX N/A
- CBIO N/A
- P/E Ratio
- BDTX $15.76
- CBIO N/A
- Revenue Growth
- BDTX N/A
- CBIO N/A
- 52 Week Low
- BDTX $1.20
- CBIO $9.81
- 52 Week High
- BDTX $4.45
- CBIO $21.40
- Technical
- Relative Strength Index (RSI)
- BDTX 55.41
- CBIO 49.46
- Support Level
- BDTX $3.71
- CBIO $12.30
- Resistance Level
- BDTX $4.08
- CBIO $12.84
- Average True Range (ATR)
- BDTX 0.24
- CBIO 0.72
- MACD
- BDTX -0.04
- CBIO 0.07
- Stochastic Oscillator
- BDTX 35.90
- CBIO 66.55
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under the pipeline are BDTX-4933 and BDTX-1535.
About CBIO Crescent Biopharma Inc. Common Stock
Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent believes CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. Crescent is advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.